Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemotrizinol MUsT PK Study
NCT04355286Phase 1Completed
- Sponsor
- DSM-Firmenich
- Start
- Nov 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bemcentinib in sunburn (4 arms), sponsored by DSM-Firmenich. Primary endpoint: Plasma Pharmacokinetic Assessment of Bemotrizinol. Started Nov 2020; status: completed.
02
Drugs
bemcentinib
03
Conditions
sunburn
Beyond the preview
Go deeper on NCT04355286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04355286.